REG - Verici Dx PLC - Result of AGM
RNS Number : 1866ZVerici Dx PLC19 May 2021Verici Dx plc
("Verici Dx" or the "Company")
Result of AGM
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at today's Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM will be made available on the Company's website: https://vericidx.com/
Enquiries:
Verici Dx
Sara Barrington, CEO
Via Walbrook PR
Julian Baines, Chairman
N+1 Singer (Nominated Adviser & Broker)
Tel: 020 7496 3000
Aubrey Powell / Justin McKeegan / Tom Salvesen
Walbrook PR Limited
Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen
Mob: 07980 541 893 / 07748 651 727
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDRAGBSGDUXBBDGBC
Recent news on Verici Dx
See all newsREG - Verici Dx PLC - Holding(s) in Company
AnnouncementREG - Verici Dx PLC - Holding(s) in Company
AnnouncementREG - Verici Dx PLC - Holding(s) in Company
AnnouncementREG - Verici Dx PLC - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 20/02/2024
Announcement